InvoRed

InvoRed is a biotechnology company focused on developing a new class of broad-spectrum antiviral and oncology therapeutics by targeting the host enzyme inosine-5'-monophosphate dehydrogenase (IMPDH). By inhibiting IMPDH, the company's small molecule candidates aim to deplete the intracellular guanine nucleotide pools required for viral replication and rapid cancer cell proliferation. This host-targeting approach is designed to provide a high barrier to resistance, making it effective against a wide range of viral threats, including RSV, influenza, and coronaviruses. InvoRed's lead programs are currently in the pre-clinical stage, with a focus on optimizing oral delivery and safety profiles. The company leverages deep expertise in nucleotide metabolism to address significant unmet needs in infectious disease and solid tumors.